LATEST NEWS
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity

View Resource PDF
View Resource

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.

CONTACT US